Search results for " Drug"

showing 10 items of 3138 documents

A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematolog…

2006

Abstract Purpose: LBH589 is a novel histone deacetylase inhibitor that inhibits proliferation and induces apoptosis in tumor cell lines. In this phase I study, LBH589 was administered i.v. as a 30-minute infusion on days 1 to 7 of a 21-day cycle. Experimental Design: Fifteen patients (median age, 63 years; range, 42-87 years) with acute myeloid leukemia (13 patients), acute lymphocytic leukemia (1 patient), or myelodysplastic syndrome (1 patient) were treated with LBH589 at the following dose levels (mg/m2): 4.8 (3 patients), 7.2 (3 patients), 9.0 (1 patient), 11.5 (3 patient), and 14.0 (5 patients). The levels of histone acetylation were measured using quantitative flow cytometry and plasm…

AdultCancer ResearchIndolesMaximum Tolerated Dosemedicine.drug_classApoptosisPharmacologyHydroxamic AcidsDrug Administration ScheduleHistonesStructure-Activity Relationshipchemistry.chemical_compoundPredictive Value of TestsPanobinostatAcute lymphocytic leukemiaPanobinostatBiomarkers TumormedicineHumansEnzyme InhibitorsAgedCell ProliferationAged 80 and overDose-Response Relationship Drugbusiness.industryHistone deacetylase inhibitorArea under the curveQTcF ProlongationMyeloid leukemiaMiddle AgedPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseHypokalemiaHistone Deacetylase InhibitorsLeukemiaTreatment OutcomeOncologychemistryCinnamatesLeukemia MyeloidMyelodysplastic SyndromesAcute DiseaseInjections IntravenousImmunologymedicine.symptombusinessFollow-Up StudiesClinical Cancer Research
researchProduct

Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation.

2002

PURPOSE: To study safety, feasibility, and biologic activity of adenovirus-mediated p53 gene transfer in patients with bladder cancer. PATIENTS AND METHODS: Twelve patients with histologically confirmed bladder cancer scheduled for cystectomy were treated on day 1 with a single intratumoral injection of SCH 58500 (rAd/p53) at cystoscopy at one dose level (7.5 × 1011 particles) or a single intravesical instillation of SCH 58500 with a transduction-enhancing agent (Big CHAP) at three dose levels (7.5 × 1011 to 7.5 × 1013 particles). Cystectomies were performed in 11 patients on day 3, and transgene expression, vector distribution, and biologic markers of transgene activity were assessed by m…

AdultCancer ResearchPathologymedicine.medical_specialtymedicine.medical_treatmentGenetic enhancementGenetic VectorsUrologyCystectomyAdenoviridaeCystectomymedicineHumansNeoplasm InvasivenessAgedDNA PrimersBiologic markerAged 80 and overUrinary bladderBladder cancermedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryReverse Transcriptase Polymerase Chain ReactionGenetic transferGene Transfer TechniquesCystoscopyGenetic TherapyMiddle Agedmedicine.diseaseGenes p53medicine.anatomical_structureAdministration IntravesicalOncologyUrinary Bladder NeoplasmsImmunohistochemistrybusinessJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

Soluble and nuclear oestrogen receptor status of advanced endometrial cancer in relation to subsequent clinical prognosis

1987

Both soluble and nuclear oestrogen receptors have been measured in at least two separate sections from 72 endometrial cancers and 12 normal endometria. Concentration of oestrogen receptor is shown to be, in our hands, more meaningful when expressed per unit DNA than per unit protein, whether for soluble or nuclear receptor. Endometrial cancer cells from the central part of the tumour are shown to be receptor negative more frequently than those from peripheral tumour. Thus, in large cancers, biopsies from different areas are required before a tumour can be correctly designated as receptor positive, heterogeneous or receptor negative. The intratumoral variation of receptor status may relate t…

AdultCancer ResearchReceptor Statusmedicine.medical_specialtymedicine.drug_classestradiol h 3estrogen receptorBiologyEndometriumEndometriumCytosolInternal medicineestradiolmedicineHumansradioisotopeReceptorAgedCell NucleusEndometrial cancerMiddle Agedmedicine.diseasePrognosisunclassified drugMenopauseCell nucleusmedicine.anatomical_structureEndocrinologyOncologyNuclear receptorReceptors EstrogenSolubilityEstrogenUterine NeoplasmsCancer researchFemalediethylstilbestrolMenopauseResearch Article
researchProduct

Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study.

2002

<i>Objective:</i> This study was designed to determine the maximum tolerable dose (MTD) of gemcitabine plus docetaxel, both given on a weekly schedule, in patients with pretreated metastatic breast cancer (MBC). <i>Methods:</i> Heavily pretreated patients with MBC, aged 18–75 years with World Health Organization performance status of 0–2 were enrolled. Three escalating weekly doses of docetaxel (30, 35 and 40 mg/m<sup>2</sup>) followed by a weekly fixed dose of gemcitabine, 800 mg/m<sup>2</sup>, were administered on days 1, 8 and 15 of a 28-day cycle. Dose-limiting toxicity (DLT) included grade >3 hematologic toxicity and grade >2 stomat…

AdultCancer Researchmedicine.medical_specialtyLung NeoplasmsPaclitaxelmedicine.drug_classmedicine.medical_treatmentBone NeoplasmsBreast NeoplasmsDocetaxelWorld Health OrganizationAntimetaboliteGastroenterologyDeoxycytidineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasisAgedChemotherapyPerformance statusDose-Response Relationship Drugbusiness.industryLiver NeoplasmsGeneral MedicineMiddle Agedmedicine.diseaseMetastatic breast cancerGemcitabineGemcitabineSurgeryRegimenTreatment OutcomeOncologyDocetaxelLymphatic MetastasisToxicityFemaleTaxoidsbusinessmedicine.drugOncology
researchProduct

Central action of cinnarizine and flunarizine: A saccadic eye movement study

1994

The mechanism of action of flunarizine (FZ) and cinnarizine (CZ) on the CNS is not fully understood. Computer analysis of saccadic eye movements (SEM) provides a sensitive and objective method for evaluating drug effect on the function of specific brain structures. This study aimed to assess the effect of a single oral dose of FZ (20 mg) and CZ (150 mg) on CNS function by means of computer analysis of SEM. Ten healthy volunteers were studied according to a double-blind, cross-over, placebo-controlled design. Peak saccadic velocity (PSV), which is related to the function of a specific group of burst neurons located in the brain stem, was significantly reduced by FZ. No significant effect of …

AdultCentral Nervous SystemMaleCinnarizineCentral nervous systemAdministration OralCinnarizinePlacebosDouble-Blind MethodmedicineSaccadesHumansPharmacology (medical)FlunarizinePharmacologyCross-Over StudiesDose-Response Relationship Drugbusiness.industryEye movementCalcium Channel BlockersSaccadic maskingElectrophysiologymedicine.anatomical_structureMechanism of actionSaccadeNeurology (clinical)medicine.symptombusinessNeuroscienceFlunarizinemedicine.drug
researchProduct

Genomic analysis of the emergence and evolution of multidrug resistance during a Klebsiella pneumoniae outbreak including carbapenem and colistin res…

2014

et al.

AdultDNA BacterialMaleMicrobiology (medical)CarbapenemAntibiotic resistanceKlebsiella pneumoniaeMolecular Sequence DataNonsense mutationFosfomycinDisease OutbreaksMicrobiologyEvolution MolecularPlasmidAntibiotic resistanceMutation RateOutbreak genomicsmedicineHumansPharmacology (medical)AgedPharmacologyGeneticsbiologyColistinHypermutationSequence Analysis DNAMiddle Agedbiochemical phenomena metabolism and nutritionbiology.organism_classificationDrug Resistance MultipleAnti-Bacterial AgentsKlebsiella InfectionsMultiple drug resistanceKlebsiella pneumoniaeInfectious DiseasesCarbapenemsKlebsiella pneumoniae genomeColistinbacteriaFemaleGenome Bacterialmedicine.drugJournal of Antimicrobial Chemotherapy
researchProduct

Clinical and Microbiologic Effects of Subgingival Controlled-Release Delivery of Chlorhexidine Chip in the Treatment of Periodontitis: A Multicenter …

2008

Background: The main therapeutic approach for periodontal diseases is mechanical treatment of root surfaces via scaling and root planing (SRP). Multicenter clinical trials have demonstrated that the adjunctive use of a chlorhexidine (CHX) chip is effective in improving clinical results compared to SRP alone. However, some recent studies failed to confirm these clinical results, and conflicting results were reported regarding the effects of the CHX chip on subgingival microflora. The aim of this study was to provide further data on the clinical and microbiologic effects of CHX chips when used as an adjunct to SRP. Methods: A total of 116 systemically healthy individuals with moderate to adva…

AdultDNA BacterialMalemedicine.drug_classBleeding on probingColony Count MicrobialDental PlaqueDentistryStatistics Nonparametriclaw.inventionBacteria AnaerobicScaling and root planingAntisepticRandomized controlled triallawChlorhexidine/therapeutic use controlled clinical trial drug delivery system periodontitis/therapymedicineHumansSingle-Blind MethodperiodontitisAgedPeriodontitischlorexidine; periodontitis; periodontitis/therapy; controlled clinical trial; drug delivery systems; chlorhexidine/therapeutic usebusiness.industryChlorhexidineChlorhexidinePeriodontologyMiddle Agedmedicine.diseaseClinical trialDelayed-Action PreparationsMultivariate AnalysisAnti-Infective Agents LocalDental ScalingPeriodonticsFemalePeriodontal Indexmedicine.symptombusinessmedicine.drugJournal of Periodontology
researchProduct

Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema

2005

BACKGROUND: Abdominal edema attacks in patients with hereditary angioedema are often extremely painful, associated with vomiting and diarrhea, and have a high potential for causing recurrent disability of the patient. STUDY DESIGN AND METHODS: Intraindividual comparison of retrospective data in 75 hereditary angioedema patients comprising 4,834 abdominal attacks treated with C1 inhibitor concentrate versus 17,444 untreated abdominal attacks. RESULTS: The mean duration of abdominal attacks was 92.0 hours (SD, 40.8 hr) when untreated compared to 39.9 hours (SD, 30.0 hr) when treated. Patients reported a mean maximal pain score of 8.6 (SD, 1.7; range, 1-10) for untreated attacks compared to 4.…

AdultDiarrheaAbdominal painTime FactorsAdolescentVomitingHypovolemiaImmunologyUnconsciousnessComplement C1 Inactivator ProteinsDrug Administration ScheduleInjectionsC1-inhibitorEcallantideHypovolemiaEdemamedicineHumansImmunology and AllergyAngioedemaChildAdverse effectSerpinsRetrospective StudiesDose-Response Relationship Drugbiologybusiness.industryInfantHematologymedicine.diseaseAbdominal PainTreatment OutcomePatient SatisfactionChild PreschoolAnesthesiaHereditary angioedemaVomitingbiology.proteinmedicine.symptombusinessComplement C1 Inhibitor ProteinBed Restmedicine.drugTransfusion
researchProduct

Gallstone dissolution with chenodeoxycholic acid. A clinical study.

1980

Out of 95 patients with radiolucent gallstones who enrolled in a clinical study with chenodeoxycholic acid (CDC) for gallstone dissolution 75 patients with cholecystolithiasis completed 12 months of treatment. As a side effect 31% of patients reported intermittent diarrhea which did not cause cessation of therapy or missing of work. The incidence of biliary colic was markedly decreased during treatment in comparison to the rate in the year before. From more than 20 laboratory values checked before start and every 3 months during therapy only aminotransferases increased up to 3 fold in 20% of patients. gamma-GT elevated in 31% of patients before treatment improved in half of these patients d…

AdultDiarrheaMalemedicine.medical_specialtyAdolescentBiliary colicBody weightChenodeoxycholic AcidGastroenterologyClinical studyGallstone dissolutionchemistry.chemical_compoundCholelithiasisChenodeoxycholic acidInternal medicineDrug DiscoverymedicineHumansIn patientGenetics (clinical)AgedDiminutionDose-Response Relationship Drugbusiness.industryBody WeightGeneral MedicineGallstonesMiddle Agedmedicine.diseasechemistrySolubilityMolecular MedicineFemalemedicine.symptombusinessConstipationKlinische Wochenschrift
researchProduct

Effect of loperamide on jejunal electrolyte and water transport, prostaglandin E 2-induced secretion and intestinal transit time in man

1991

Jejunal perfusion was performed in 12 healthy volunteers to evaluate the dose dependent effects of loperamide on intestinal absorption, stimulated secretion and transit. In 6 volunteers intestinal perfusion of the jejunal segment with isotonic NaCl solution was followed by addition of loperamide in increasing doses (2–8 mg·l−1). The volunteers were pretreated with 1 mg·l−1 prostaglandin E2 (PgE2) in the perfusate before addition of 4 mg·l−1 loperamide. Phenolsulphonphtalein (PSP) boluses (2 ml) were given to measure mean transit time (MTT). Loperamide 2 mg·l−1 converted the minor secretion after perfusion with the standard solution (water −1.45 ml·min−1, Na −0.09 and Cl −0.04 mmol·min−1) to…

AdultDiarrheaMalemedicine.medical_specialtyLoperamideAdolescentAbsorption (skin)LoperamideDinoprostoneIntestinal absorptionJejunumChloridesInternal medicinemedicineHumansPharmacology (medical)Prostaglandin E2Gastrointestinal TransitPharmacologyWater transportDose-Response Relationship DrugChemistrySodiumBiological TransportGeneral MedicineWater-Electrolyte BalanceJejunumEndocrinologymedicine.anatomical_structureIntestinal AbsorptionMechanism of actionmedicine.symptomPerfusionmedicine.drugEuropean Journal of Clinical Pharmacology
researchProduct